Unlock this StockReport nowClick to Unlock

GLG Pharma SA Share Price

GLG PLN0.58 -0.0  -1.0%
03/06/19
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg
Revenue PLNm
Operating Profit PLNm
Net Profit PLNm
EPS Reported PLN
EPS Normalised PLN
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps PLN
Capex ps PLN
Free Cashflow ps PLN
Dividends
Dividend ps PLN
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc PLNm
Working Capital PLNm
Net Fixed Assets PLNm
Net Debt PLNm
Book Value PLNm
Average Shares m
Book Value ps PLN +130.5%

FINANCIAL BRIEF: For the three months ended 31 March 2019, GLG Pharma SA revenues was not reported. Net loss decreased 86% to PLN41K. Lower net loss reflects Salaries decrease from PLN68K (expense) to PLN0K, Other Expense decrease from PLN13K (expense) to PLN0K, Material Cost decrease from PLN4K (expense) to PLN0K. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score  
E+
E+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Mar '19) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a () () () () () ()
Consensus Estimate
1m Change
3m Change
Broker Consensus Trend
Broker Recommendations for GLG Pharma SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
There are no named brokers.

Profile Summary

GLG Pharma SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the research and development of therapies based on small molecules and formulations, which inhibit dysfunctional Signal Transducer and Activators of Transcription (STAT3) signaling. STAT3 is a signaling protein, which optimizes the human cell growth. The Company develops projects related to cancer and kidney disease treatment, as well as other drug applications. Its pipeline includes STAT3 inhibitors that mainly aim at treatment of chronic lymphatic leukemia (CLL), polycystic kidney disease (PKD) and triple negative breast cancer (TNBC). The Company performs clinical trials in laboratories located in Poland and the United States.

Directors: Izabela Roman (CSU) , H. Gabriel (VMG) , Katarzyna Malarowska (CAO) , Timothy Krochuk (SUB) , Manuel Worcel (SUB) 78,

No. of Employees: n/a No. of Shareholders: n/a


Last Annual December 31st, 2018
Last Interim March 31st, 2019
Incorporated May 23, 2011
Public Since February 6, 2012
Shares in Issue 8,800,001
Free Float 8.80m (100.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Warsaw Stock Exchange
Eligible for an ISA? a SIPP?

GLG Share Price Performance GLG Share Price Quote
PLN0.58
-0.0  -1.0%
Traded 4:35pm · Minimum 15 min delayed · NMS:

Latest GLG News Announcements (delayed)

Upcoming GLG Events

Recent ↓
Friday 29th June, 2018
GLG Pharma SA Annual Shareholders Meeting
Thursday 1st February, 2018
GLG Pharma SA Extraordinary Shareholders Meeting
Friday 30th June, 2017
GLG Pharma SA Annual Shareholders Meeting
Monday 5th September, 2016
GLG Pharma SA Annual Shareholders Meeting
Tuesday 26th July, 2016
GLG Pharma SA Reverse Split For GLG.WA


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy GLG

Access GLG Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis